Forma Therapeutics Holdings, Inc. (FMTX)
Stock Price:
$43.54 USD
-0.80 (-1.80%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed
After-hours: $43.56 +0.02 (0.05%) Jul 10, 4:11 PM
Key Info
| Market Cap |
1.81B |
| Revenue (ttm) |
28.55M |
| Net Income (ttm) |
n/a |
| Shares Out |
38.58M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 10, 2020 |
| Last Price |
$43.54 |
| Previous Close |
$44.34 |
| Change ($) |
-0.80 |
| Change (%) |
-1.80% |
| Day's Open |
44.35 |
| Day's Range |
43.13 - 46.74 |
| Day's Volume |
571,202 |
| 52-Week Range |
37.50 - 50.00 |
More Stats
| Market Cap |
1.81B |
| Enterprise Value |
1.66B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
38.58M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
162,102 |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
63.31 |
| PB Ratio |
11.82 |
| Revenue |
28.55M |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
142.44M |
| Net Cash / Share |
3.43 |
| Gross Margin |
-37.68% |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 101 | 164 |
| Revenue Growth | -38.72% | - |
| Gross Profit | 101 | 164 |
| Operating Income | -40.45 | 9.69 |
| Net Income | -34.79 | 5.29 |
| Shares Outstanding | 10.90 | 10.90 |
| Earnings Per Share | -4.93 | -0.04 |
| Operating Cash Flow | -34.49 | -133 |
| Capital Expenditures | -0.53 | -3.39 |
| Free Cash Flow | -35.02 | -136 |
| Cash & Equivalents | 173 | 152 |
| Net Cash / Debt | 173 | 152 |
| Assets | 183 | 263 |
| Liabilities | 26.66 | 246 |
| Book Value | 18.25 | -48.87 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Forma Therapeutics Holdings, Inc. |
| Country |
United States |
| Employees |
77 |
| CEO |
Frank D. Lee |
Stock Information
| Ticker Symbol |
FMTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: FMTX |
| IPO Date |
June 19, 2020 |
Description
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing FT-2102, an oral selective small molecule investigational agent that is designed to bind to and inhibit mutated IDH1 enzymes, which is being evaluated in a Phase 2 trial for relapsed/refractory AML, as well as an exploratory Phase 1 trial for glioma; and FT-4101 and FT-8225, which are selective fatty acid synthase inhibitors. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.